ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 943,53
0,34%
DAX
17 932,17
-1,10%
Brent Oil
83,325
-2,99%
Bitcoin
57 776,93
-4,67%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. NGM Biopharmaceuticals Inc (NGM)

  7. NGM Biopharmaceuticals Inc (NGM) Actualités

NGM NGM Biopharmaceuticals Inc

1,54
0,00 (0,00%)
Dernière mise à jour : 02:00:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
NGM Biopharmaceuticals Inc NGM NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 1,54 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,54
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
05/4/202415:19GLOBENGM Bio Announces Closing of Tender Offer
19/3/202422:30GLOBENGM Bio to Present Two Posters Highlighting Clinical Data..
11/3/202421:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202421:13EDGAR2Form 8-K - Current report
11/3/202421:05GLOBENGM Bio Provides Recent Business Highlights and Reports..
08/3/202423:32EDGAR2Form SC 13E3 - Going private transaction by certain issuers
08/3/202423:21EDGAR2Form SC 14D9 - Solicitation, recommendation statements
26/2/202423:11EDGAR2Form SC14D9C - Written communication relating to third party..
26/2/202423:01EDGAR2Form 8-K - Current report
26/2/202415:03GLOBENGM Bio Has Entered into a Definitive Agreement and Plan of..
20/2/202422:01GLOBENGM Bio to Participate in the Cowen 44th Annual Health Care..
15/2/202400:12EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22/1/202412:09EDGAR2Form 8-K - Current report
19/1/202400:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202422:47GLOBENGM Bio to Participate in the B. Riley Securities 4th Annual..
09/1/202414:00GLOBENGM Bio Announces New Clinical Data from Ongoing Trial of..
02/1/202413:30EDGAR2Form 8-K - Current report
04/12/202323:19EDGAR2Form 8-K - Current report
04/12/202322:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202315:45GLOBENGM Bio Presents Positive Phase 2b Results from the ALPINE 4..
09/11/202300:13EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/11/202300:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202300:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202300:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202322:05GLOBENGM Bio to Participate in Upcoming Investor Conferences
02/11/202321:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:06EDGAR2Form 8-K - Current report
02/11/202321:01GLOBENGM Bio Reports Third Quarter 2023 Financial Results and..
17/10/202323:28EDGAR2Form 8-K - Current report
11/10/202322:05GLOBENGM Bio Announces Oral Plenary Presentation of Data from..
27/9/202314:30PRNUSAlexandria Real Estate Equities, Inc.'s One-of-a-Kind,..
11/9/202322:01EDGAR2Form 8-K/A - Current report: [Amend]
11/8/202322:08EDGAR2Form 8-K - Current report
07/8/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
04/8/202323:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/8/202322:01EDGAR2Form S-3/A - Registration statement under Securities Act of..
03/8/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:07EDGAR2Form 8-K - Current report
03/8/202322:01GLOBENGM Bio Reports Second Quarter 2023 Financial Results and..
25/5/202315:00GLOBENGM Bio to Participate in Upcoming Investor Conferences
08/5/202322:05GLOBENGM Bio Announces Presentation of Data from Phase 2..
04/5/202322:05GLOBENGM Bio Reports First Quarter 2023 Financial Results and..

Dernières Valeurs Consultées

NASDAQ
NGM
NGM Biopharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés